(Total Views: 418)
Posted On: 05/30/2019 8:32:18 PM
Post# of 154979
When I get time I might do a little more research about how these top selling drugs did in mice studies.
https://www.genengnews.com/a-lists/top-10-bes...s-of-2018/
Ranking #15 through #11 among cancer best-sellers are Takeda/Johnson & Johnson’s Velcade® (bortezomib); Incyte/Novartis’ Jakafi®/Jakavi® (ruxolitinib); Genentech (Roche)’s Perjeta (pertuzumab); Merck & Co.’s Gardasil/Gardasil 9; and J&J’s Zytiga® (abiraterone acetate). The treatments generated between $2.274 billion and $3.498 billion last year.
10. Xtandi® (enzalutamide)
Astellas Pharma and Pfizer
Type of Drug: Androgen receptor inhibitor
2018 Sales: $3.624 billion (¥327.8 billion [$2.925 billion Astellas + $0.699 billion Pfizer)
2017 Sales: $3.116 billion (¥282.8 billion [$2.526 billion Astellas + $0.590 billion Pfizer)
% Change: 16.3%
9. Ibrance® (palbociclib)
Pfizer
Type of Drug: Kinase inhibitor
2018 Sales: $4.118 billion 1
2017 Sales: $3.126 billion 1
% Change: 31.7%
8. Neulasta/Peglasta (pegfilgrastim)
Amgen and Kyowa Hakko Kirin
Type of Drug: Leukocyte growth factor
2018 Sales: $4.684 billion ($4.475 billion Amgen + $0.209 billion [¥23.1 billion] Kyowa Hakko Kirin)
2017 Sales: $4.716 billion ($4.534 billion Amgen + $0.182 billion [¥20.1 billion] Kyowa Hakko Kirin)
% Change: -0.7%
7. Imbruvica® (ibrutinib)
Pharmacyclics (AbbVie) and Johnson & Johnson (J&J)
Type of Drug: Kinase inhibitor
2018 Sales: $6.205 billion ($3.590 billion Pharmacyclics [AbbVie] + $2.615 billion J&J)
2017 Sales: $4.466 billion ($2.573 billion Pharmacyclics [AbbVie] + $1.893 billion J&J)
% Change: 38.9%
6. Rituxan®/MabThera (rituximab)
Genentech (Roche) and Biogen 2
Type of Drug: CD20-directed cytolytic antibody
2018 Sales: $6.750 billion [CHF 6.752 billion] 2
2017 Sales: $7.298 billion [CHF 7.300 billion] 2
% Change: -7.5%
5. Avastin
Roche
Type of Drug: Vascular endothelial growth factor–directed antibody
2018 Sales: $6.822 billion (CHF 6.849 billion)
2017 Sales: $6.662 billion (CHF 6.688 billion)
% Change: 2.4%
4. Herceptin
Roche (Genentech)
Type of Drug: HER2/neu receptor antagonist
2018 Sales: $6.951 billion (CHF 6.982 billion)
2017 Sales: $6.983 billion (CHF 7.014 billion)
% Change: -0.5%
3. Keytruda
Merck & Co.
Type of Drug: Programmed death receptor-1 (PD-1)-blocking antibody
2018 Sales: $7.171 billion
2017 Sales: $3.809 billion
% Change: 88.3%
2. Opdivo
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical
Type of Drug: Programmed death receptor-1 (PD-1) blocking antibody
2018 Sales: $7.570 billion ($6.735 billion BMS + $835 million [¥92.5 billion] Ono)
2017 Sales: $5.763 billion ($4.948 billion BMS + $815 million [¥90.2 billion] Ono)
% Change: 31.4%
1. Revlimid
Celgene
Type of Drug: Thalidomide analogue
2018 Sales: $9.685 billion
2017 Sales: $8.187 billion
% Change: 18.3%
https://www.genengnews.com/a-lists/top-10-bes...s-of-2018/
Ranking #15 through #11 among cancer best-sellers are Takeda/Johnson & Johnson’s Velcade® (bortezomib); Incyte/Novartis’ Jakafi®/Jakavi® (ruxolitinib); Genentech (Roche)’s Perjeta (pertuzumab); Merck & Co.’s Gardasil/Gardasil 9; and J&J’s Zytiga® (abiraterone acetate). The treatments generated between $2.274 billion and $3.498 billion last year.
10. Xtandi® (enzalutamide)
Astellas Pharma and Pfizer
Type of Drug: Androgen receptor inhibitor
2018 Sales: $3.624 billion (¥327.8 billion [$2.925 billion Astellas + $0.699 billion Pfizer)
2017 Sales: $3.116 billion (¥282.8 billion [$2.526 billion Astellas + $0.590 billion Pfizer)
% Change: 16.3%
9. Ibrance® (palbociclib)
Pfizer
Type of Drug: Kinase inhibitor
2018 Sales: $4.118 billion 1
2017 Sales: $3.126 billion 1
% Change: 31.7%
8. Neulasta/Peglasta (pegfilgrastim)
Amgen and Kyowa Hakko Kirin
Type of Drug: Leukocyte growth factor
2018 Sales: $4.684 billion ($4.475 billion Amgen + $0.209 billion [¥23.1 billion] Kyowa Hakko Kirin)
2017 Sales: $4.716 billion ($4.534 billion Amgen + $0.182 billion [¥20.1 billion] Kyowa Hakko Kirin)
% Change: -0.7%
7. Imbruvica® (ibrutinib)
Pharmacyclics (AbbVie) and Johnson & Johnson (J&J)
Type of Drug: Kinase inhibitor
2018 Sales: $6.205 billion ($3.590 billion Pharmacyclics [AbbVie] + $2.615 billion J&J)
2017 Sales: $4.466 billion ($2.573 billion Pharmacyclics [AbbVie] + $1.893 billion J&J)
% Change: 38.9%
6. Rituxan®/MabThera (rituximab)
Genentech (Roche) and Biogen 2
Type of Drug: CD20-directed cytolytic antibody
2018 Sales: $6.750 billion [CHF 6.752 billion] 2
2017 Sales: $7.298 billion [CHF 7.300 billion] 2
% Change: -7.5%
5. Avastin
Roche
Type of Drug: Vascular endothelial growth factor–directed antibody
2018 Sales: $6.822 billion (CHF 6.849 billion)
2017 Sales: $6.662 billion (CHF 6.688 billion)
% Change: 2.4%
4. Herceptin
Roche (Genentech)
Type of Drug: HER2/neu receptor antagonist
2018 Sales: $6.951 billion (CHF 6.982 billion)
2017 Sales: $6.983 billion (CHF 7.014 billion)
% Change: -0.5%
3. Keytruda
Merck & Co.
Type of Drug: Programmed death receptor-1 (PD-1)-blocking antibody
2018 Sales: $7.171 billion
2017 Sales: $3.809 billion
% Change: 88.3%
2. Opdivo
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical
Type of Drug: Programmed death receptor-1 (PD-1) blocking antibody
2018 Sales: $7.570 billion ($6.735 billion BMS + $835 million [¥92.5 billion] Ono)
2017 Sales: $5.763 billion ($4.948 billion BMS + $815 million [¥90.2 billion] Ono)
% Change: 31.4%
1. Revlimid
Celgene
Type of Drug: Thalidomide analogue
2018 Sales: $9.685 billion
2017 Sales: $8.187 billion
% Change: 18.3%
(0)
(0)
